毒品管制局被指控妨碍大麻研究长达十年之久,影响严重疾病治疗。 DEA accused of decade-long obstruction of marijuana research, impacting severe disease treatments.

美国缉毒署(DEA)面临十年来阻碍大麻研究的指责, The U.S. Drug Enforcement Administration (DEA) faces accusations of obstructing marijuana research for a decade, denying FDA-approved cannabis treatments to patients with severe conditions like Huntington's disease and Multiple Sclerosis. 尽管有扩大研究的希望,但据称缉毒局偏向于不活跃的公司,而不是像MMJ生物药草种植这样的合法申请者,因为MMJ生物药草种植拥有完全符合要求的设施。 Despite promising to expand research, the DEA allegedly favored inactive companies over legitimate applicants like MMJ BioPharma Cultivation, which had a fully compliant facility. 随着毒品管制署新任署长Terrance Cole的到来, 有希望有一个转折点, 可以把病人放在政治之上。 With the incoming DEA Administrator Terrance Cole, there's hope for a turning point that could prioritize patients over politics.